Avacta Group Share News (AVCT)

Avacta Group Information

Buy AVCT Shares
Add AVCT to Watchlist
Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 43.00

Bid: 42.50

Ask: 43.50

Change: 0.10 (0.23%)

Spread: 1.00 (2.353%)

Open: 43.00

High: 44.10

Low: 42.50

Prev. Close: 44.00

Last checked at -

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Mon, 18th Mar 2024 14:31

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.

Current stock price: 51.00 pence, down 2.4% on Monday afternoon

12-month change: down 58%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

More News

8 Feb 2021 11:25

Avacta enters commercial partnership with Mologic

(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.

8 Feb 2021 10:46

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

8 Feb 2021 09:37

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

1 Feb 2021 14:37

TRADING UPDATES: Asiamet Hits Back At Shareholder; Hardide Raises Cash

1 Feb 2021 09:25

Avacta joint venture with Daewoong raises $7.3m in series A funding

(Sharecast News) - Biotherapeutics developer Avacta Group announced on Monday that its joint venture with Daewoong Pharmaceutical, AffyXell Therapeutics, has closed a series A venture capital investment of $7.3m (£5.32m) to further develop its pipeline of next generation cell and gene therapies.

28 Jan 2021 14:42

IN BRIEF: Avacta Lands Deal With Bruker To Assess SARS-CoV-2 Test

7 Jan 2021 13:51

IN BRIEF: Avacta Group Enters License Agreement With Point Biopharma

7 Jan 2021 08:58

Avacta enters licence agreement with Point Biopharma

(Sharecast News) - Cancer therapy and diagnostics developer Avacta Group has entered into a licence agreement with Point Biopharma, it announced on Thursday, to provide access to its 'preCISION' technology for the development of tumour-activated radiopharmaceuticals.

23 Dec 2020 19:50

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

23 Dec 2020 08:56

Avacta submits clinical trial application for 'AVA6000' prodrug

(Sharecast News) - Cancer therapy developer Avacta Group has submitted a clinical trial application in the UK for a phase 1 first-in-human open label dose-escalation and expansion study of its lead 'preCISION' prodrug, 'AVA6000', in patients with locally-advanced or metastatic selected solid tumours, it announced on Wednesday.

21 Dec 2020 18:10

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

21 Dec 2020 09:49

Avacta enters 'Affimer' licensing deal with Astrea Bioseparations

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a licensing agreement with Astrea Bioseparations, it announced on Monday, for the use of the 'Affimer' platform in affinity purification applications.

23 Nov 2020 15:20

Avacta reports 'significant progress' on Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group announced "significant progress" in the development of a scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions on Monday.

22 Oct 2020 15:53

UK DIRECTOR DEALINGS SUMMARY: Dunkerton Buys More Superdry Shares

1 Oct 2020 06:40

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Avacta enters commercial partnership with Mologic

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

TRADING UPDATES: Asiamet Hits Back At Shareholder; Hardide Raises Cash

Avacta joint venture with Daewoong raises $7.3m in series A funding

IN BRIEF: Avacta Lands Deal With Bruker To Assess SARS-CoV-2 Test

IN BRIEF: Avacta Group Enters License Agreement With Point Biopharma

Avacta enters licence agreement with Point Biopharma

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

Avacta submits clinical trial application for 'AVA6000' prodrug

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

Avacta enters 'Affimer' licensing deal with Astrea Bioseparations

Avacta reports 'significant progress' on Covid-19 test

UK DIRECTOR DEALINGS SUMMARY: Dunkerton Buys More Superdry Shares

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Login to your account

Quickpicks are a member only feature

Login to your account